Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial

OBJECTIVES: To investigate patient characteristics predictive of response to secukinumab in patients with psoriatic arthritis (PsA) with axial manifestations. METHODS: In a post-hoc analysis from the MAXIMISE trial (NCT02721966) in patients with PsA and axial manifestations, we tested the hypothesis...

Descripción completa

Detalles Bibliográficos
Autores principales: Baraliakos, Xenofon, Pournara, Effie, Gossec, Laure, Mease, Philip J, White, Roisin, O’Brien, Eamonn, Schulz, Barbara, Marzo-Ortega, Helena, Coates, Laura C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297227/
https://www.ncbi.nlm.nih.gov/pubmed/35850974
http://dx.doi.org/10.1136/rmdopen-2022-002303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297227/
https://www.ncbi.nlm.nih.gov/pubmed/35850974
http://dx.doi.org/10.1136/rmdopen-2022-002303

Ejemplares similares